Clinical Trial: A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT04846842) titled 'A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer' on April 12.

Brief Summary: This phase II clinical trial studies the safety and effect of Gimatecan in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or peritoneal cancer.

The chemotherapy will be given every four weeks.This study is a single-arm, multi-center research design.

Study Type: Interventional

Condition: * Epithelial Ovarian Cancer

* Fallopian Tube Cancer

* Peritoneal Cancer

Intervention: Drug: Gimatecan

Patients will receive gimatecan orally at the fixed dose level on day 1-5 ever...